Zevra Therapeutics (ZVRA) Other Non-Current Liabilities (2014 - 2026)

Zevra Therapeutics' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• Quarterly Other Non-Current Liabilities fell 88.5% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 88.5% YoY) and the FY2025 annual result came in at $7.0 million, down 60.52% from the prior year.
• Other Non-Current Liabilities was $1.9 million for Q1 2026 at Zevra Therapeutics, down from $7.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $17.8 million in Q4 2024 and bottomed at $25000.0 in Q4 2022.
• A 5-year average of $7.5 million and a median of $6.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Peak annual rise in Other Non-Current Liabilities reached 90485.71% in 2022, while the deepest fall reached 93.43% in 2022.
• Zevra Therapeutics' Other Non-Current Liabilities stood at $25000.0 in 2022, then surged by 64300.0% to $16.1 million in 2023, then increased by 10.58% to $17.8 million in 2024, then sank by 60.52% to $7.0 million in 2025, then tumbled by 73.55% to $1.9 million in 2026.
• Business Quant data shows ZVRA's Other Non-Current Liabilities at $1.9 million in Q1 2026, $7.0 million in Q4 2025, and $4.0 million in Q3 2025.